Details

GPCRs in the human genome<br> GPCR Three-dimensional structures: from bovine rhodopsin to homology models<br> Orphan GPCRs and ligand design <br> GPCR databases: From genes to proteins, from proteins to ligands <br> Druggability of human GPCRs <br> Molecular Mechanisms of GPCR activation & Oligomerisation <br> Allosteric regulation of GPCRs <br> Ligand-Based rational design <br> Receptor-based rational design <br> Chemogenomics approaches to ligand design and target priorisation <br> GPCR targeted libraries and privileged structures <br>

"Die vielfach farbigen Abbildungen und Übersichten sind von hoher Qualität. Die Literatur wie gewohnt aktuell und umfangreich."<br> Umwelt & Gesundheit<br>

Didier Rognan leads the Drug Bioinformatics Group at the Laboratory for Molecular Pharmacochemistry in Illkirch (France). He obtained a graduate degree in Pharmacy from the University of Rennes and completed his PhD in Medicinal Chemistry at the University of Strasbourg under the supervision of Camille G. Wermuth in 1989. Moving to the Swiss Federal Institute of Technology in Zürich he became Assistant Professor at the ETH before being named a research director at the CRNS in Illkirch near Strasbourg in 2000.<br> Professor Rognan is mainly interested in all aspects (method development, applications) of protein-based drug design and virtual screening.

G protein-coupled receptors (GPCRs) are important "switches" in biological signal transduction and constitute the most numerous protein class in higher organisms, reflecting their involvement in the hormonal regulation of virtually all body processes. This regulatory function makes them prime drug targets, and many blockbuster drugs act either directly or indirectly on GPCRs. Yet it is only with the recent elucidation of the rhodopsin structure that these receptors have become amenable to a rational drug design.<br> This is the first work to describe in detail the structure-based rational approach to GPCR drug design. Based on recent examples from academia and the pharmaceutical industry, it demonstrates how to apply the whole range of bioinformatics, chemoinformatics and molecular modeling tools to the rational design of novel drugs targeting GPCRs. <br> From the contents:<br> * GPCRs in the human genome<br> * GPCR Three-dimensional structures: from bovine rhodopsin to homology models<br> * Orphan GPCRs and ligand design <br> * GPCR databases: From genes to proteins, from proteins to ligands <br> * Druggability of human GPCRs <br> * Molecular Mechanisms of GPCR activation & Oligomerisation <br> * Allosteric regulation of GPCRs <br> * Ligand-based rational design <br> * Receptor-based rational design <br> * Chemogenomics approaches to ligand design and target priorisation <br> * GPCR targeted libraries and privileged structures<br> Essential reading for medicinal chemists, biochemists, pharmaceutical chemists, biotechnologists and drug designers working in the pharmaceutical and biotechnological industries.

DE